tetano
Editor, Senior Moderator
Cell Rep
. 2021 Dec 23;110256.
doi: 10.1016/j.celrep.2021.110256. Online ahead of print.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Yaochang Yuan[SUP] 1 [/SUP], Xiantao Zhang[SUP] 1 [/SUP], Ran Chen[SUP] 1 [/SUP], Yuzhuang Li[SUP] 1 [/SUP], Bolin Wu[SUP] 1 [/SUP], Rong Li[SUP] 1 [/SUP], Fan Zou[SUP] 2 [/SUP], Xiancai Ma[SUP] 1 [/SUP], Xuemei Wang[SUP] 1 [/SUP], Qier Chen[SUP] 1 [/SUP], Jieyi Deng[SUP] 1 [/SUP], Yongli Zhang[SUP] 1 [/SUP], Tao Chen[SUP] 1 [/SUP], Yingtong Lin[SUP] 1 [/SUP], Shumei Yan[SUP] 3 [/SUP], Xu Zhang[SUP] 1 [/SUP], Congrong Li[SUP] 4 [/SUP], Xiuqing Bu[SUP] 4 [/SUP], Yi Peng[SUP] 4 [/SUP], Changwen Ke[SUP] 5 [/SUP], Kai Deng[SUP] 6 [/SUP], Ting Pan[SUP] 1 [/SUP], Xin He[SUP] 1 [/SUP], Yiwen Zhang[SUP] 7 [/SUP], Hui Zhang[SUP] 8 [/SUP]
Affiliations
Abstract
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.
Keywords: B.1.351 variants; SARS-CoV-2 variants; bivalent nanoparticle vaccine.
. 2021 Dec 23;110256.
doi: 10.1016/j.celrep.2021.110256. Online ahead of print.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Yaochang Yuan[SUP] 1 [/SUP], Xiantao Zhang[SUP] 1 [/SUP], Ran Chen[SUP] 1 [/SUP], Yuzhuang Li[SUP] 1 [/SUP], Bolin Wu[SUP] 1 [/SUP], Rong Li[SUP] 1 [/SUP], Fan Zou[SUP] 2 [/SUP], Xiancai Ma[SUP] 1 [/SUP], Xuemei Wang[SUP] 1 [/SUP], Qier Chen[SUP] 1 [/SUP], Jieyi Deng[SUP] 1 [/SUP], Yongli Zhang[SUP] 1 [/SUP], Tao Chen[SUP] 1 [/SUP], Yingtong Lin[SUP] 1 [/SUP], Shumei Yan[SUP] 3 [/SUP], Xu Zhang[SUP] 1 [/SUP], Congrong Li[SUP] 4 [/SUP], Xiuqing Bu[SUP] 4 [/SUP], Yi Peng[SUP] 4 [/SUP], Changwen Ke[SUP] 5 [/SUP], Kai Deng[SUP] 6 [/SUP], Ting Pan[SUP] 1 [/SUP], Xin He[SUP] 1 [/SUP], Yiwen Zhang[SUP] 7 [/SUP], Hui Zhang[SUP] 8 [/SUP]
Affiliations
- PMID: 34990583
- DOI: 10.1016/j.celrep.2021.110256
Abstract
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.
Keywords: B.1.351 variants; SARS-CoV-2 variants; bivalent nanoparticle vaccine.